

# Resource Summary Report

Generated by ASWG on Sep 3, 2026

## reMYND

RRID:SCR\_003824

Type: Tool

---

### Proper Citation

reMYND (RRID:SCR\_003824)

---

### Resource Information

**URL:** <http://www.remynd.com/>

**Proper Citation:** reMYND (RRID:SCR\_003824)

**Description:** Organization that drives the development of disease-modifying treatments against Alzheimer's, Parkinson's, Diabetes and other protein misfolding disorders through two independently managed business units: \* Contract Research: The in-vivo Contract Research Organization (CRO) helps its clients to assess the pharmacokinetics and -dynamics of their experimental treatments against Alzheimer's disease. The main focus is on efficacy testing of candidate drugs in reMYND's proprietary Alzheimer mouse models expressing the clinical APP-London allele as single transgene or in combination with clinical alleles of human PS1 and TAU. \* Drug Discovery: The Drug Discovery and Development Unit (DDD) focuses on disease-modifying treatments against protein-misfolding disorders, such as Alzheimer's disease (tau), Parkinson's disease (-synuclein), and Diabetes. In addition, reMYND grants licenses and markets commercial kits of RadarScreen, a technology for rapid and cost-effective identification of genotoxic liabilities in early stage drug discovery. reMYND has been substantially supported by grants from IWT and from The Michael J Fox Foundation.

**Abbreviations:** reMYND

**Synonyms:** reMYND NV

**Resource Type:** commercial organization

**Keywords:** protein misfolding

**Related Condition:** Alzheimer's disease, Parkinson's disease, Diabetes

**Funding:** IWT ;  
Michael J. Fox Foundation for Parkinson's Research

**Resource Name:** reMYND

**Resource ID:** SCR\_003824

**Alternate IDs:** nlx\_158130

**Record Creation Time:** 20220129T080221+0000

**Record Last Update:** 20260829T182144+0000

---

## Ratings and Alerts

No rating or validation information has been found for reMYND.

No alerts have been found for reMYND.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 1 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [ASWG](#) .

Albert M, et al. (2019) Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody. Brain : a journal of neurology, 142(6), 1736.